{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:38:32Z","timestamp":1791905912989,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology of Japan","doi-asserted-by":"crossref","award":["23592437"],"award-info":[{"award-number":["23592437"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology of Japan","doi-asserted-by":"crossref","award":["25861473"],"award-info":[{"award-number":["25861473"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology of Japan","doi-asserted-by":"crossref","award":["25861471"],"award-info":[{"award-number":["25861471"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology of Japan","doi-asserted-by":"crossref","award":["25893229"],"award-info":[{"award-number":["25893229"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology of Japan","doi-asserted-by":"crossref","award":["11114014"],"award-info":[{"award-number":["11114014"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Project for Development of Innovative Research on Cancer Therapeutics"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ygyno.2015.04.015","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T16:30:45Z","timestamp":1429720245000},"page":"174-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["PI3K\/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-\u03b1\/VEGF pathway in endometrial cancer"],"prefix":"10.1016","volume":"138","author":[{"given":"Aki","family":"Miyasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2468-9573","authenticated-orcid":false,"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenbun","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinami","family":"Makii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Arimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kuramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Wada-Hiraike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.04.015_bb0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00441-005-1109-5","article-title":"Endometrial cancer","volume":"322","author":"Ryan","year":"2005","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2014.06.003","article-title":"Endometrial cancer: a review and current management strategies: part II","volume":"134","author":"SGO Clinical Practice Endometrial Cancer Working Group","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ijrobp.2005.02.004","article-title":"Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer","volume":"63","author":"Lin","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post-operative radiation therapy in endometrial carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2014.06.026","article-title":"Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations","volume":"134","author":"Wik","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0030","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/onc.2009.474","article-title":"Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway","volume":"29","author":"Murayama-Hosokawa","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2015.35","article-title":"Just how accurate are the major risk stratification systems for early-stage endometrial cancer?","volume":"112","author":"Bendifallah","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0090-8258(92)90045-K","article-title":"Radiation sensitivity of endometrial carcinoma in vitro","volume":"44","author":"Rantanen","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0045","first-page":"55","article-title":"Allelic imbalance in hMLH1 or BRCA2 loci associated with response of cervical and endometrial cancer to radiotherapy","volume":"10","author":"Arvanitis","year":"2002","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijrobp.2009.09.035","article-title":"Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer","volume":"76","author":"Bilbao","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0055","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/sj.onc.1206677","article-title":"P53 and radiation responses","volume":"22","author":"Fei","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc992","article-title":"The role of p53 in determining sensitivity to radiotherapy","volume":"3","author":"Gudkov","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl. 10","key":"10.1016\/j.ygyno.2015.04.015_bb0065","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/1097-0142(19951115)76:10+<2034::AID-CNCR2820761321>3.0.CO;2-U","article-title":"Molecular basis of endometrial cancer","volume":"76","author":"Berchuck","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1101\/sqb.2005.70.044","article-title":"Cancer targets in the RAS pathway","volume":"70","author":"Rodriguez-Viciana","year":"2005","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0080","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3892\/or.2013.2515","article-title":"Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer","volume":"30","author":"Ikeda","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0085","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","article-title":"High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma","volume":"65","author":"Oda","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0090","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-08-0755","article-title":"PIK3CA cooperates with other phosphatidylinositol 3\u2032-kinase pathway mutations to effect oncogenic transformation","volume":"68","author":"Oda","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.bjc.6605109","article-title":"The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas","volume":"101","author":"Shoji","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1667\/0033-7587(2003)159[0283:SARIAO]2.0.CO;2","article-title":"Stress and radiation-induced activation of multiple intracellular signaling pathways","volume":"159","author":"Dent","year":"2003","journal-title":"Radiat. Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0105","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1038\/sj.onc.1206701","article-title":"MAPK pathways in radiation responses","volume":"22","author":"Dent","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4161\/cbt.64","article-title":"Pharmacologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms","volume":"1","author":"Qiao","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0115","doi-asserted-by":"crossref","first-page":"14212","DOI":"10.1074\/jbc.M412569200","article-title":"Delayed activation of insulin-like growth factor-1 receptor\/Src\/MAPK\/Egr-1 signaling regulates clusterin expression, a pro-survival factor","volume":"280","author":"Criswell","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0120","first-page":"4278","article-title":"The RAS radiation resistance pathway","volume":"61","author":"Gupta","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0125","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1038\/sj.onc.1206699","article-title":"The RAS signal transduction pathway and its role in radiation sensitivity","volume":"22","author":"McKenna","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0130","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijrobp.2010.12.065","article-title":"Targeting the AKT\/GSK3beta\/cyclin D1\/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy","volume":"80","author":"Shimura","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0135","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.cellsig.2007.07.025","article-title":"PI3K\/PTEN\/AKT signaling regulates prostate tumor angiogenesis","volume":"19","author":"Fang","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6603201","article-title":"HIF-1 and tumour radiosensitivity","volume":"95","author":"Moeller","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0145","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.4161\/cbt.8.21.9988","article-title":"Modulating the tumor microenvironment to increase radiation responsiveness","volume":"8","author":"Karar","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0150","doi-asserted-by":"crossref","first-page":"685308","DOI":"10.1155\/2013\/685308","article-title":"Microenvironment and radiation therapy","volume":"2013","author":"Yoshimura","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0155","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1078-0432.CCR-05-1084","article-title":"Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines","volume":"12","author":"Lee","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0160","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1078-0432.CCR-07-0955","article-title":"Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer","volume":"14","author":"Manegold","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0165","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-08-2954","article-title":"In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase 1\/2 kinase","volume":"15","author":"Chung","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037431","article-title":"Genotype-dependent efficacy of a dual PI3K\/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas","volume":"7","author":"Shoji","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0175","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1749-6632.1991.tb37884.x","article-title":"Establishment and characterization of human endometrial cancer cell lines","volume":"622","author":"Kuramoto","year":"1991","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0180","first-page":"6506","article-title":"Analysis of the p53 gene in human uterine carcinoma cell lines","volume":"51","author":"Yaginuma","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-0774.2003.tb00128.x","article-title":"VEGF expression and its regulation by p53 gene transfection in endometrial carcinoma cells","volume":"16","author":"Fujisawa","year":"2003","journal-title":"Hum. Cell"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087220","article-title":"Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K\/mTOR inhibitor DS-7423","volume":"9","author":"Kashiyama","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-14-179","article-title":"Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells","volume":"14","author":"Miyasaka","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1088\/0031-9155\/37\/2\/010","article-title":"Calculation of radiation dose enhancement factors for dose enhancement therapy of brain tumours","volume":"37","author":"Solberg","year":"1992","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0205","doi-asserted-by":"crossref","first-page":"7486","DOI":"10.1038\/sj.onc.1206949","article-title":"The role of p53 in chemosensitivity and radiosensitivity","volume":"22","author":"El-Deiry","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0210","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0092-8674(00)00073-8","article-title":"p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53","volume":"102","author":"Oda","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0215","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ijrobp.2005.08.014","article-title":"Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism","volume":"63","author":"Gottschalk","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijrobp.2005.02.008","article-title":"Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy","volume":"64","author":"Kim","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0225","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1158\/1078-0432.CCR-12-2716","article-title":"PI3K\/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer","volume":"19","author":"Herzog","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0230","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-13-0010","article-title":"PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy","volume":"12","author":"Chow","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0235","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1158\/0008-5472.CAN-09-0823","article-title":"Dual phosphoinositide 3-kinase\/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations","volume":"69","author":"Konstantinidou","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0240","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cbr.2012.1443","article-title":"NVP-BEZ235, dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3","volume":"28","author":"Zhu","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0245","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/1078-0432.CCR-13-1607","article-title":"Inhibition of DNA double-strand break repair by the dual PI3K\/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma","volume":"20","author":"del Alcazar CR","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0250","first-page":"39","article-title":"Novel PI3K and mTOR inhibitor NVP-BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditions","volume":"8","author":"Kuger","year":"2014","journal-title":"Breast Cancer (Auckl.)"},{"key":"10.1016\/j.ygyno.2015.04.015_bb0255","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.4161\/cbt.8.21.9988","article-title":"Modulating the tumor microenvironment to increase radiation responsiveness","volume":"8","author":"Karar","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0260","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-12-0858","article-title":"Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy","volume":"18","author":"Meijer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0265","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0270","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.015_bb0275","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1054\/bjoc.2001.2166","article-title":"Effect of VEGF receptor inhibitor PTK787\/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth","volume":"85","author":"Hess","year":"2001","journal-title":"Br. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815008355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815008355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T15:55:49Z","timestamp":1656172549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815008355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0090825815008355"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K\/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-\u03b1\/VEGF pathway in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}